


WHAT IS CLAIMED IS:

1. A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein:

X^1 is N or CT^4 ;

Q^1 is an N-containing 5- to 6-membered heteroaryl or an N-containing 5- to 6-membered heterocycloalkyl, each optionally substituted with one R^9 and further optionally substituted with 1, 2, 3, or 4 R^{10} ;

each of T^1 , T^2 , T^3 , and T^4 is independently selected from the group consisting of H, halogen, -CN, C_{1-4} alkyl, C_{1-4} haloalkyl, cyclopropyl, fluorocyclopropyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, and -C(=O)-O-(C_{1-4} alkyl);

each of R^1 and R^2 is independently selected from the group consisting of H, halogen, -CN, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, -C(=O)OH, and C(=O)-O-(C_{1-4} alkyl), wherein each of said C_{1-6} alkyl and C_{3-6} cycloalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from halo, -OH, -CN, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy;

each of R^3 and R^4 is independently selected from the group consisting of H, halogen, -OH, -NO₂, -CN, -SF₅, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, a 4- to 10-membered heterocycloalkyl, -N(R^5)(R^6), -N(R^7)(C(=O) R^8), -C(=O)-N(R^5)(R^6), -C(=O)- R^8 , -C(=O)-OR⁸, -N(R^7)(S(=O)₂ R^8), -S(=O)₂-N(R^5)(R^6), -SR⁸, and -OR⁸, wherein each of said C_{1-6} alkyl, C_{3-7} cycloalkyl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CN, -OH, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{3-6} cycloalkyl, -N(R^5)(R^6), -N(R^7)(C(=O) R^8), -C(=O)-OR⁸, -C(=O)H, -C(=O) R^8 , -C(=O)N(R^5)(R^6), -N(R^7)(S(=O)₂ R^8), -S(=O)₂-N(R^5)(R^6), -SR⁸, and -OR⁸;

R^5 is H, C_{1-4} alkyl, C_{1-4} haloalkyl, or C_{3-7} cycloalkyl;

R^6 is H or selected from the group consisting of C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-7} cycloalkyl, a 4- to 10-membered heterocycloalkyl, C_{6-10} aryl, a 5- to 10-membered heteroaryl, (C_{3-7} cycloalkyl)- C_{1-4} alkyl-, (4- to 10-membered heterocycloalkyl)- C_{1-4} alkyl-, (C_{6-10} aryl)- C_{1-4} alkyl-,

and (5- to 10-membered heteroaryl)-C₁₋₄ alkyl-, wherein each of the selections from the group is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of -OH, -CN, C₁₋₄ alkyl, C₃₋₇ cycloalkyl, C₁₋₄ hydroxylalkyl, -S-C₁₋₄ alkyl, -C(=O)H, -C(=O)-C₁₋₄ alkyl, -C(=O)-O-C₁₋₄ alkyl, -C(=O)-NH₂, -C(=O)-N(C₁₋₄ alkyl)₂, C₁₋₄ haloalkyl, C₁₋₄ alkoxy, and C₁₋₄ haloalkoxy;

or R⁵ and R⁶ together with the N atom to which they are attached form a 4- to 10-membered heterocycloalkyl or a 5- to 10-membered heteroaryl, each optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from the group consisting of halogen, -OH, oxo, -C(=O)H, -C(=O)OH, -C(=O)-C₁₋₄ alkyl, -C(=O)-NH₂, -C(=O)-N(C₁₋₄ alkyl)₂, -CN, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxylalkyl, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;

R⁷ is selected from the group consisting of H, C₁₋₄ alkyl, and C₃₋₇ cycloalkyl;

R⁸ is selected from the group consisting of C₁₋₆ alkyl, C₃₋₇ cycloalkyl, a 4- to 14-membered heterocycloalkyl, C₆₋₁₀ aryl, a 5- to 10-membered heteroaryl, (C₃₋₇ cycloalkyl)-C₁₋₄ alkyl-, (4- to 10-membered heterocycloalkyl)-C₁₋₄ alkyl-, (C₆₋₁₀ aryl)-C₁₋₄ alkyl-, and (5- to 10-membered heteroaryl)-C₁₋₄ alkyl-, wherein each of the selections from the group is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CF₃, -CN, -OH, oxo, -S-C₁₋₄ alkyl, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₇ cycloalkyl, C₁₋₄ alkoxy, and C₁₋₄ haloalkoxy;

R⁹ is C₁₋₄ alkyl, C₁₋₄ haloalkyl, -CN, -SF₅, -N(R⁵)(R⁶), C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₇ cycloalkoxy, or C₃₋₇ cycloalkyl, wherein each of the C₁₋₄ alkyl and C₃₋₇ cycloalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from the group consisting of halogen, -N(R⁵)(R⁶), C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₇ cycloalkyl, C₁₋₄ alkoxy, and C₁₋₄ haloalkoxy;

each R¹⁰ is independently selected from the group consisting of halogen, -OH, -CN, -SF₅, -NO₂, oxo, thiono, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxylalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₇ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, a 4- to 10-membered heterocycloalkyl, a 5- to 10-membered heteroaryl, (C₃₋₇ cycloalkyl)-C₁₋₄ alkyl-, (4- to 10-membered heterocycloalkyl)-C₁₋₄ alkyl-, (C₆₋₁₀ aryl)-C₁₋₄ alkyl-, (5- to 10-membered heteroaryl)-C₁₋₄ alkyl-, -N(R⁵)(R⁶), -N(R⁷)(C(=O)R⁸), -S(=O)₂N(R⁵)(R⁶), -C(=O)-N(R⁵)(R⁶), -C(=O)-R⁸, -C(=O)-OR⁸, -SR⁸, and -OR⁸, wherein each of said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl, 4- to 10-membered heterocycloalkyl, 5- to 10-membered heteroaryl, (C₃₋₇ cycloalkyl)-C₁₋₄ alkyl-, (4- to 10-membered heterocycloalkyl)-C₁₋₄ alkyl-, (C₆₋₁₀ aryl)-C₁₋₄ alkyl-, and (5- to 10-membered heteroaryl)-C₁₋₄ alkyl- is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of halogen, OH, -CN, -NO₂, C₁₋₄ alkyl, C₁₋₄ hydroxylalkyl, C₁₋₄ alkoxy, -N(R⁵)(R⁶), -S-(C₁₋₄ alkyl), -S(=O)₂-(C₁₋₄ alkyl), C₆₋₁₀ aryloxy, [(C₆₋₁₀ aryl)-C₁₋₄ alkyloxy- optionally substituted with 1 or 2 C₁₋₄


alkyl], oxo, -C(=O)H, -C(=O)-C₁₋₄ alkyl, -C(=O)O-C₁₋₄ alkyl, -C(=O)NH₂, -NHC(=O)H, -NHC(=O)-(C₁₋₄ alkyl), C₃₋₇ cycloalkyl, a 5- or 6-membered heteroaryl, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;

or R⁹ and an adjacent R¹⁰ together with the two ring atoms on Q¹ to which they are attached form a fused benzene ring or a fused 5- or 6-membered heteroaryl, each optionally substituted with 1, 2, 3, 4, or 5 independently selected R^{13a}; and


each R^{10a} is independently selected from the group consisting of halogen, -OH, -N(R⁵)(R⁶), -C(=O)OH, -C(=O)-C₁₋₄ alkyl, -C(=O)-NH₂, -C(=O)-N(C₁₋₄ alkyl)₂, -CN, -SF₅, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxylalkyl, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;

provided that the compound of Formula I is not 4-(4-imidazol-1-yl-phenoxy)-3-methyl-1*H*-pyrazolo[4,3-*c*]pyridine.

2. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein X¹ is N.
3. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein X¹ is CT⁴.
4. The compound of any one of Claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein each of T¹, T², T³, and T⁴ is independently selected from the group consisting of H, F, -CN, methoxy, C₁ fluoroalkoxy, methyl, and C₁ fluoroalkyl,
5. The compound of any one of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein T² is H and T³ is H.
6. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula Ia:



7. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula Ib:



8. The compound of any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein:

each of R^1 and R^2 is independently selected from the group consisting of H, halogen, -CN, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, and C_{3-4} cycloalkyl;

each of R^3 and R^4 is independently selected from the group consisting of H, halogen, -OH, -CN, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{3-4} cycloalkyl, a 4- to 7-membered heterocycloalkyl, $-N(R^5)(R^6)$, and $-OR^8$,

each of R^5 and R^6 independently is H or selected from the group consisting of C_{1-4} alkyl, C_{1-4} haloalkyl, and C_{3-7} cycloalkyl;

or R^5 and R^6 together with the N atom to which they are attached form a 4- to 7-membered heterocycloalkyl or a 5-membered heteroaryl, each optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CN, C_{1-4} alkyl, C_{1-4} alkoxy, C_{3-6} cycloalkyl, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy; and


R^8 is selected from the group consisting of C_{1-4} alkyl, C_{3-6} cycloalkyl, a 4- to 7-membered heterocycloalkyl, phenyl, and a 5- to 6-membered heteroaryl, each optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CN, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-6} cycloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy.

9. The compound of any one of Claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein each of R^1 and R^2 is independently H or halogen.

10. The compound of any one of Claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R^3 is H and R^4 is H, halogen, -CN, methyl, or C_1 haloalkyl.

11. The compound of any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein Q^1 is an N-containing 5- to 6-membered heteroaryl or an N-containing 5- to 6-membered heterocycloalkyl, each substituted with one R^9 and further optionally substituted with 1, 2, 3, or 4 R^{10} .

12. The compound of any one of Claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein:



Q¹ is a moiety of ("Moiety M¹");

ring Q^{1a} is an N-containing 5- to 6-membered heteroaryl or an N-containing 5- to 6-membered heterocycloalkyl;

===== represents a single bond or double bond;

Z¹ is C;

Z² is C or N;

R⁹ is C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₇ cycloalkyl, -CN, -N(R⁵)(R⁶), C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, or C₃₋₇ cycloalkoxy, wherein each of the C₁₋₄ alkyl and C₃₋₇ cycloalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from the group consisting of halogen, -N(R⁵)(R⁶), C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₇ cycloalkyl, C₁₋₄ alkoxy, and C₁₋₄ haloalkoxy;

each R¹⁰ is independently selected from the group consisting of halogen, -OH, -CN, -NO₂, oxo, thiono, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxylalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₇ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, a 4- to 10-membered heterocycloalkyl, a 5- to 10-membered heteroaryl, (C₃₋₇ cycloalkyl)-C₁₋₄ alkyl-, (4- to 10-membered heterocycloalkyl)-C₁₋₄ alkyl-, (C₆₋₁₀ aryl)-C₁₋₄ alkyl-, (5- to 10-membered heteroaryl)-C₁₋₄ alkyl-, (5- to 10-membered heteroaryl)-C₂₋₄ alkenyl-, -N(R⁵)(R⁶), -N(R⁷)(C(=O)R⁸), -S(=O)₂N(R⁵)(R⁶), -C(=O)-N(R⁵)(R⁶), -C(=O)-R⁸, -C(=O)-OR⁸, and -OR⁸, wherein each of said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl, 4- to 10-membered heterocycloalkyl, 5- to 10-membered heteroaryl, (C₃₋₇ cycloalkyl)-C₁₋₄ alkyl-, (4- to 10-membered heterocycloalkyl)-C₁₋₄ alkyl-, (C₆₋₁₀ aryl)-C₁₋₄ alkyl-, (5- to 10-membered heteroaryl)-C₁₋₄ alkyl-, and (5- to 10-membered heteroaryl)-C₂₋₄ alkenyl- is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of halogen, OH, -CN, -NO₂, C₁₋₄ alkyl, C₁₋₄ hydroxylalkyl, C₁₋₄ alkoxy, -N(R⁵)(R⁶), -S-(C₁₋₄ alkyl), -S(=O)₂-(C₁₋₄ alkyl), C₆₋₁₀ aryloxy, (C₆₋₁₀ aryl)-C₁₋₄ alkyloxy- optionally substituted with 1 or 2 C₁₋₄ alkyl, oxo, -C(=O)H, -C(=O)-C₁₋₄ alkyl, -C(=O)O-C₁₋₄ alkyl, -C(=O)NH₂, -NHC(=O)H, -NHC(=O)-(C₁₋₄ alkyl), C₃₋₇ cycloalkyl, a 5- or 6-membered heteroaryl, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;


or R⁹ and the adjacent R¹⁰ together with the two ring atoms on ring Q^{1a} to which they are attached form a fused benzene ring or a fused 5- or 6-membered heteroaryl, each optionally substituted with 1, 2, 3, 4, or 5 independently selected R^{10a};

each R^{10a} is independently selected from the group consisting of halogen, -OH, -C(=O)OH, -C(=O)-C₁₋₄ alkyl, -C(=O)-NH₂, -C(=O)-N(C₁₋₄ alkyl)₂, -CN, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxylalkyl, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy; and
m is 0, 1, 2, 3, or 4.

13. The compound of any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein Q^1 or ring Q^{1a} is an optionally substituted pyridinyl, pyrimidinyl, pyridazinyl, or pyrazinyl.

14. The compound of Claim 12, or a pharmaceutically acceptable salt thereof, wherein Moiety M^1 is selected from the group consisting of quinolinyl, isoquinolinyl, 1*H*-imidazo[4,5-*c*]pyridinyl, imidazo[1,2-*a*]pyridinyl, 1*H*-pyrrolo[3,2-*c*]pyridinyl, imidazo[1,2-*a*]pyrazinyl, imidazo[2,1-*c*][1,2,4]triazinyl, imidazo[1,5-*a*]pyrazinyl, imidazo[1,2-*a*]pyrimidinyl, 1*H*-indazolyl, 9*H*-purinyl, imidazo[1,2-*a*]pyrimidinyl, [1,2,4]triazolo[1,5-*a*]pyrimidinyl, isoxazolo[5,4-*c*]pyridazinyl, isoxazolo[3,4-*c*]pyridazinyl, and [1,2,4]triazolo[4,3-*b*]pyridazinyl, each optionally substituted with 1, 2, or 3 R^{10} and further optionally substituted with 1 or 2 R^{10a} ; or wherein Moiety M^1 is selected from the group consisting of pyrimidinyl, pyrazinyl, pyridinyl, pyridazinyl, 1*H*-pyrazolyl, 1*H*-pyrrolyl, 4*H*-pyrazolyl, 1*H*-imidazolyl, 1*H*-imidazolyl, 3-oxo-2*H*-pyridazinyl, 1*H*-2-oxo-pyrimidinyl, 1*H*-2-oxo-pyridinyl, 2,4(1*H*,3*H*)-dioxo-pyrimidinyl, and 1*H*-2-oxo-pyrazinyl, each substituted with R^9 and further optionally substituted with 1, 2, or 3 R^{10} .

15. The compound of Claim 12, or a pharmaceutically acceptable salt thereof, wherein:




16. The compound of any one of Claims 1 to 15, or a pharmaceutically acceptable salt thereof, wherein R⁹ is C₁₋₄ alkyl or -CN; and each R¹⁰ is independently C₁₋₄ alkyl.
17. A compound of Claim 1 selected from:
- 4-[4-(4,6-dimethylpyrimidin-5-yl)-3-fluorophenoxy]-1H-pyrrolo[3,2-c]pyridine;
(+)-4,6-dimethyl-5-[2-methyl-4-(1H-pyrazolo[4,3-c]pyridin-4-yloxy)phenyl]pyridazin-3(2H)-one;
(-)-4,6-dimethyl-5-[2-methyl-4-(1H-pyrazolo[4,3-c]pyridin-4-yloxy)phenyl]pyridazin-3(2H)-one;
4-[4-(4,6-dimethylpyrimidin-5-yl)-3-methylphenoxy]-1H-pyrrolo[3,2-c]pyridine;
4-[4-(4,6-dimethylpyrimidin-5-yl)-3-methylphenoxy]-1H-pyrazolo[4,3-c]pyridine;
4,6-dimethyl-5-[4-(1H-pyrrolo[3,2-c]pyridin-4-yloxy)phenyl]pyridazin-3(2H)-one;
(-)-1,5-dimethyl-6-[2-methyl-4-(1H-pyrazolo[4,3-c]pyridin-4-yloxy)phenyl]pyrimidine-2,4(1H,3H)-dione;
4,6-dimethyl-5-[2-methyl-4-(1H-pyrrolo[3,2-c]pyridin-4-yloxy)phenyl]pyridazin-3(2H)-one, ENT-1;
4,6-dimethyl-5-[2-methyl-4-(1H-pyrrolo[3,2-c]pyridin-4-yloxy)phenyl]pyridazin-3(2H)-one, ENT-2
4-[4-(4,6-dimethyl-1-oxidopyrimidin-5-yl)-3-methylphenoxy]-1H-pyrazolo[4,3-c]pyridine;
6-methyl-5-[2-methyl-4-(1H-pyrrolo[3,2-c]pyridin-4-yloxy)phenyl]imidazo[1,2-a]pyrazine;
4-[4-(4,6-dimethylpyrimidin-5-yl)phenoxy]-1H-pyrrolo[3,2-c]pyridine;
2-(4,6-dimethylpyrimidin-5-yl)-5-(1H-pyrrolo[3,2-c]pyridin-4-yloxy)benzonitrile;
4-[3-chloro-4-(4,6-dimethylpyrimidin-5-yl)phenoxy]-1H-pyrrolo[3,2-c]pyridine;
(-)-1,5-dimethyl-6-[2-methyl-4-(1H-pyrrolo[3,2-c]pyridin-4-yloxy)phenyl]pyrazin-2(1H)-one;
4-[4-(4,6-dimethylpyrimidin-5-yl)-3-fluorophenoxy]-1H-pyrazolo[4,3-c]pyridine;
4-[4-(4,6-dimethylpyrimidin-5-yl)-3-methoxyphenoxy]-1H-pyrazolo[4,3-c]pyridine;
4-[3-chloro-4-(4,6-dimethylpyrimidin-5-yl)phenoxy]-1H-pyrazolo[4,3-c]pyridine;
(+)-1,5-dimethyl-6-[2-methyl-4-(1H-pyrazolo[4,3-c]pyridin-4-yloxy)phenyl]pyrazin-2(1H)-one;
4,6-dimethyl-5-[4-(1H-pyrazolo[4,3-c]pyridin-4-yloxy)phenyl]pyridazin-3(2H)-one; and
1,5-dimethyl-6-[4-(1H-pyrazolo[4,3-c]pyridin-4-yloxy)phenyl]pyrimidine-2,4(1H,3H)-dione,
or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a compound according to any one of Claims 1-17 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
19. A method for treating a D1-mediated (or D1-associated) disorder in a mammal, which method comprises administering to said mammal a therapeutically effective amount of a compound according to any one of Claims 1-17 or a pharmaceutically acceptable salt thereof.
20. A method for treating a disorder in a human, which method comprises administering to said human a therapeutically effective amount of a compound according to any one of Claims 1-17 or a pharmaceutically acceptable salt thereof, wherein the disorder is selected from schizophrenia (e.g., cognitive and negative symptoms in schizophrenia), cognitive impairment [e.g., cognitive impairment associated with schizophrenia, cognitive impairment associated with AD, cognitive impairment associated with PD, cognitive impairment associated with pharmacotherapy therapy (e.g., D2 antagonist therapy)], attention deficit hyperactivity disorder (ADHD), impulsivity, compulsive gambling, overeating, autism spectrum disorder, mild cognitive impairment (MCI), age-related cognitive decline, dementia (e.g., senile dementia, HIV-associated dementia, Alzheimer's dementia, Lewy body dementia, vascular dementia, or frontotemporal dementia), restless leg syndrome (RLS), Parkinson's disease, Huntington's chorea, anxiety, depression (e.g., age-related depression), major depressive disorder (MDD), treatment resistant depression (TRD), bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction (e.g., erectile dysfunction or post-SSRI sexual dysfunction), migraine, systemic lupus erythematosus (SLE), hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.

CLAIMS

1. A compound of Formula I:



or a pharmaceutically acceptable salt thereof, wherein:

X^1 is N or CT^4 ;

Q^1 is an N-containing 5- to 6-membered heteroaryl or an N-containing 5- to 6-membered heterocycloalkyl, each optionally substituted with one R^9 and further optionally substituted with

1, 2, 3, or 4 R^{10} ;

T^2 is H;

T^3 is H;

each of T^1 and T^4 is independently selected from the group consisting of H, F, -CN, methoxy, C_1 fluoroalkoxy, methyl, and C_1 fluoroalkyl;

each of R^1 and R^2 is independently selected from the group consisting of H, halogen, -CN, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl, -C(=O)OH, and C(=O)-O-(C_{1-4} alkyl), wherein each of said C_{1-6} alkyl and C_{3-6} cycloalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from halo, -OH, -CN, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy;

each of R^3 and R^4 is independently selected from the group consisting of H, halogen, -OH, -NO₂, -CN, -SF₅, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, a 4- to 10-membered heterocycloalkyl, -N(R^5)(R^6), -N(R^7)(C(=O) R^8), -C(=O)-N(R^5)(R^6), -C(=O)- R^8 , -C(=O)-OR⁸, -N(R^7)(S(=O)₂ R^8), -S(=O)₂-N(R^5)(R^6), -SR⁸, and -OR⁸, wherein each of said C_{1-6} alkyl, C_{3-7} cycloalkyl, and heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CN, -OH, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{3-6} cycloalkyl, -N(R^5)(R^6), -N(R^7)(C(=O) R^8), -C(=O)-OR⁸, -C(=O)H, -C(=O) R^8 , -C(=O)N(R^5)(R^6), -N(R^7)(S(=O)₂ R^8), -S(=O)₂-N(R^5)(R^6), -SR⁸, and -OR⁸;

R^5 is H, C_{1-4} alkyl, C_{1-4} haloalkyl, or C_{3-7} cycloalkyl;

R^6 is H or selected from the group consisting of C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-7} cycloalkyl, a 4- to 10-membered heterocycloalkyl, C_{6-10} aryl, a 5- to 10-membered heteroaryl, (C_{3-7} cycloalkyl)- C_{1-4} alkyl-, (4- to 10-membered heterocycloalkyl)- C_{1-4} alkyl-, (C_{6-10} aryl)- C_{1-4} alkyl-, and (5- to 10-membered heteroaryl)- C_{1-4} alkyl-, wherein each of the selections from the group is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of -OH, -CN, C_{1-4} alkyl, C_{3-7} cycloalkyl, C_{1-4} hydroxylalkyl, -S- C_{1-4} alkyl, -C(=O)H, -C(=O)- C_{1-4} alkyl, -C(=O)-O- C_{1-4} alkyl, -C(=O)-NH₂, -C(=O)-N(C_{1-4} alkyl)₂, C_{1-4} haloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy;

or R^5 and R^6 together with the N atom to which they are attached form a 4- to 10-membered heterocycloalkyl or a 5- to 10-membered heteroaryl, each optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from the group consisting of halogen, -OH, oxo, -C(=O)H, -C(=O)OH, -C(=O)- C_{1-4} alkyl, -C(=O)-NH₂, -C(=O)-N(C_{1-4} alkyl)₂, -CN, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} hydroxylalkyl, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy;

R^7 is selected from the group consisting of H, C_{1-4} alkyl, and C_{3-7} cycloalkyl;

R^8 is selected from the group consisting of C_{1-6} alkyl, C_{3-7} cycloalkyl, a 4- to 14-membered heterocycloalkyl, C_{6-10} aryl, a 5- to 10-membered heteroaryl, (C_{3-7} cycloalkyl)- C_{1-4} alkyl-, (4- to 10-membered heterocycloalkyl)- C_{1-4} alkyl-, (C_{6-10} aryl)- C_{1-4} alkyl-, and (5- to 10-membered heteroaryl)- C_{1-4} alkyl-, wherein each of the selections from the group is optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CF₃, -CN, -OH, oxo, -S- C_{1-4} alkyl, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-7} cycloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy;

R^9 is C_{1-4} alkyl, C_{1-4} haloalkyl, -CN, -SF₅, -N(R^5)(R^6), C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-7} cycloalkoxy, or C_{3-7} cycloalkyl, wherein each of the C_{1-4} alkyl and C_{3-7} cycloalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from the group consisting of halogen, -N(R^5)(R^6), C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-7} cycloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy;

each R^{10} is independently selected from the group consisting of halogen, -OH, -CN, -SF₅, -NO₂, oxo, thiono, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxylalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-7} cycloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{6-10} aryl, a 4- to 10-membered heterocycloalkyl, a 5- to 10-membered heteroaryl, (C_{3-7} cycloalkyl)- C_{1-4} alkyl-, (4- to 10-membered heterocycloalkyl)- C_{1-4} alkyl-, (C_{6-10} aryl)- C_{1-4} alkyl-, (5- to 10-membered heteroaryl)- C_{1-4} alkyl-, -N(R^5)(R^6), -N(R^7)(C(=O) R^8), -S(=O)₂N(R^5)(R^6), -C(=O)-N(R^5)(R^6), -C(=O)- R^8 , -C(=O)-OR⁸, -SR⁸, and -OR⁸, wherein each of said C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{6-10} aryl, 4- to 10-membered heterocycloalkyl, 5- to 10-membered heteroaryl, (C_{3-7} cycloalkyl)- C_{1-4} alkyl-, (4- to 10-membered heterocycloalkyl)- C_{1-4} alkyl-, (C_{6-10} aryl)- C_{1-4} alkyl-, and (5- to 10-membered heteroaryl)- C_{1-4} alkyl- is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting

of halogen, OH, -CN, -NO₂, C₁₋₄ alkyl, C₁₋₄ hydroxylalkyl, C₁₋₄ alkoxy, -N(R⁵)(R⁶), -S-(C₁₋₄ alkyl), -S(=O)₂-(C₁₋₄ alkyl), C₆₋₁₀ aryloxy, [(C₆₋₁₀ aryl)-C₁₋₄ alkoxy- optionally substituted with 1 or 2 C₁₋₄ alkyl], oxo, -C(=O)H, -C(=O)-C₁₋₄ alkyl, -C(=O)O-C₁₋₄ alkyl, -C(=O)NH₂, -NHC(=O)H, -NHC(=O)-(C₁₋₄ alkyl), C₃₋₇ cycloalkyl, a 5- or 6-membered heteroaryl, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;


- 5 or R⁹ and an adjacent R¹⁰ together with the two ring atoms on Q¹ to which they are attached form a fused benzene ring or a fused 5- or 6-membered heteroaryl, each optionally substituted with 1, 2, 3, 4, or 5 independently selected R^{10a}; and

each R^{10a} is independently selected from the group consisting of halogen, -OH, -N(R⁵)(R⁶), -C(=O)OH, -C(=O)-C₁₋₄ alkyl, -C(=O)-NH₂, -C(=O)-N(C₁₋₄ alkyl)₂, -CN, -SF₅, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxylalkyl, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy.

2. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein X¹ is N.


- 15 3. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein X¹ is CT⁴.

4. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula Ia:



Ia.

5. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula Ib:



Ib.

6. The compound of any one of Claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein:

each of R^1 and R^2 is independently selected from the group consisting of H, halogen, -

5 CN, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, C_{1-4} haloalkoxy, and C_{3-4} cycloalkyl;

each of R^3 and R^4 is independently selected from the group consisting of H, halogen, -OH, -CN, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, C_{3-4} cycloalkyl, a 4- to 7-membered heterocycloalkyl, $-N(R^5)(R^6)$, and $-OR^8$,

10 each of R^5 and R^6 independently is H or selected from the group consisting of C_{1-4} alkyl, C_{1-4} haloalkyl, and C_{3-7} cycloalkyl;

or R^5 and R^6 together with the N atom to which they are attached form a 4- to 7-membered heterocycloalkyl or a 5-membered heteroaryl, each optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CN, C_{1-4} alkyl, C_{1-4} alkoxy, C_{3-6} cycloalkyl, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy; and

15 R^8 is selected from the group consisting of C_{1-4} alkyl, C_{3-6} cycloalkyl, a 4- to 7-membered heterocycloalkyl, phenyl, and a 5- to 6-membered heteroaryl, each optionally substituted with 1, 2, or 3 substituents each independently selected from the group consisting of halogen, -CN, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{3-6} cycloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy.

20 7. The compound of any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein each of R^1 and R^2 is independently H or halogen.


8. The compound of any one of Claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R^3 is H and R^4 is H, halogen, -CN, methyl, or C_1 haloalkyl.

25

9. The compound of any one of Claims 1 to 8, or a pharmaceutically acceptable salt thereof, wherein Q^1 is an N-containing 5- to 6-membered heteroaryl or an N-containing 5- to 6-membered heterocycloalkyl, each substituted with one R^9 and further optionally substituted with 1, 2, 3, or 4 R^{10} .

30

10. The compound of any one of Claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein:



Q¹ is a moiety of ("Moiety M¹ⁿ");

ring Q^{1a} is an N-containing 5- to 6-membered heteroaryl or an N-containing 5- to 6-membered heterocycloalkyl;

===== represents a single bond or double bond;

5 Z¹ is C;

Z² is C or N;

R⁹ is C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₇ cycloalkyl, -CN, -N(R⁵)(R⁶), C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, or C₃₋₇ cycloalkoxy, wherein each of the C₁₋₄ alkyl and C₃₋₇ cycloalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents each independently selected from the group
10 consisting of halogen, -N(R⁵)(R⁶), C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₃₋₇ cycloalkyl, C₁₋₄ alkoxy, and C₁₋₄ haloalkoxy;

each R¹⁰ is independently selected from the group consisting of halogen, -OH, -CN, -NO₂, oxo, thiono, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ hydroxylalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₇ cycloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₆₋₁₀ aryl, a 4- to 10-membered heterocycloalkyl, a 5- to 10-
15 membered heteroaryl, (C₃₋₇ cycloalkyl)-C₁₋₄ alkyl-, (4- to 10-membered heterocycloalkyl)-C₁₋₄ alkyl-, (C₆₋₁₀ aryl)-C₁₋₄ alkyl-, (5- to 10-membered heteroaryl)-C₁₋₄ alkyl-, -N(R⁵)(R⁶), -N(R⁷)(C(=O)R⁸), -S(=O)₂N(R⁵)(R⁶), -C(=O)-N(R⁵)(R⁶), -C(=O)-R⁸, -C(=O)-OR⁸, and -OR⁸, wherein each of said C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₆₋₁₀ aryl, 4- to 10-membered heterocycloalkyl, 5- to 10-membered heteroaryl, (C₃₋₇ cycloalkyl)-C₁₋₄ alkyl-, (4- to 10-membered
20 heterocycloalkyl)-C₁₋₄ alkyl-, (C₆₋₁₀ aryl)-C₁₋₄ alkyl-, and (5- to 10-membered heteroaryl)-C₁₋₄ alkyl is optionally substituted with 1, 2, 3, or 4 substituents each independently selected from the group consisting of halogen, OH, -CN, -NO₂, C₁₋₄ alkyl, C₁₋₄ hydroxylalkyl, C₁₋₄ alkoxy, -N(R⁵)(R⁶), -S-(C₁₋₄ alkyl), -S(=O)₂-(C₁₋₄ alkyl), C₆₋₁₀ aryloxy, (C₆₋₁₀ aryl)-C₁₋₄ alkyloxy- optionally substituted with 1 or 2 C₁₋₄ alkyl, oxo, -C(=O)H, -C(=O)-C₁₋₄ alkyl, -C(=O)O-C₁₋₄ alkyl, -
25 C(=O)NH₂, -NHC(=O)H, -NHC(=O)-(C₁₋₄ alkyl), C₃₋₇ cycloalkyl, a 5- or 6-membered heteroaryl, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;

or R⁹ and the adjacent R¹⁰ together with the two ring atoms on ring Q^{1a} to which they are attached form a fused benzene ring or a fused 5- or 6-membered heteroaryl, each optionally substituted with 1, 2, 3, 4, or 5 independently selected R^{10a};

30 each R^{10a} is independently selected from the group consisting of halogen, -OH, -C(=O)OH, -C(=O)-C₁₋₄ alkyl, -C(=O)-NH₂, -C(=O)-N(C₁₋₄ alkyl)₂, -CN, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ hydroxylalkyl, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy; and


m is 0, 1, 2, 3, or 4.

11. The compound of any one of Claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein Q^1 or ring Q^{1a} is an optionally substituted pyridinyl, pyrimidinyl, pyridazinyl, or pyrazinyl.


12. The compound of Claim 10, or a pharmaceutically acceptable salt thereof, wherein Moiety M^1 is selected from the group consisting of quinolinyl, isoquinolinyl, 1*H*-imidazo[4,5-*c*]pyridinyl, imidazo[1,2-*a*]pyridinyl, 1*H*-pyrrolo[3,2-*c*]pyridinyl, imidazo[1,2-*a*]pyrazinyl,

imidazo[2,1-*c*][1,2,4]triazinyl, imidazo[1,5-*a*]pyrazinyl, imidazo[1,2-*a*]pyrimidinyl, 1*H*-indazolyl, 9*H*-purinyl, imidazo[1,2-*a*]pyrimidinyl, [1,2,4]triazolo[1,5-*a*]pyrimidinyl, isoxazolo[5,4-*c*]pyridazinyl, isoxazolo[3,4-*c*]pyridazinyl, and [1,2,4]triazolo[4,3-*b*]pyridazinyl, each optionally substituted with 1, 2, or 3 R^{10} and further optionally substituted with 1 or 2 R^{10a} ; or wherein Moiety M^1 is selected from the group consisting of pyrimidinyl, pyrazinyl, pyridinyl, pyridazinyl, 1*H*-pyrazolyl, 1*H*-pyrrolyl, 4*H*-pyrazolyl, 1*H*-imidazolyl, 1*H*-imidazolyl, 3-oxo-2*H*-pyridazinyl, 1*H*-2-oxo-pyrimidinyl, 1*H*-2-oxo-pyridinyl, 2,4(1*H*,3*H*)-dioxo-pyrimidinyl, and 1*H*-2-oxo-pyrazinyl, each substituted with R^9 and further optionally substituted with 1, 2, or 3 R^{10} .

13. The compound of Claim 10, or a pharmaceutically acceptable salt thereof, wherein:



14. The compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof wherein Q^1 is:



and R^{11} is H, C_{1-4} alkyl, C_{1-4} haloalkyl or C_{3-7} cycloalkyl.

15. The compound of any one of Claims 1 to 14, or a pharmaceutically acceptable salt thereof, wherein R^9 is C_{1-4} alkyl or $-CN$; and each R^{10} is independently C_{1-4} alkyl.

16. A compound of Claim 1 selected from:

4-[4-(4,6-dimethylpyrimidin-5-yl)-3-fluorophenoxy]-1*H*-pyrrolo[3,2-*c*]pyridine;
(+)-4,6-dimethyl-5-[2-methyl-4-(1*H*-pyrazolo[4,3-*c*]pyridin-4-yloxy)phenyl]pyridazin-3(2*H*)-

10 one;

(-)-4,6-dimethyl-5-[2-methyl-4-(1*H*-pyrazolo[4,3-*c*]pyridin-4-yloxy)phenyl]pyridazin-3(2*H*)-one;

4-[4-(4,6-dimethylpyrimidin-5-yl)-3-methylphenoxy]-1*H*-pyrrolo[3,2-*c*]pyridine;

4-[4-(4,6-dimethylpyrimidin-5-yl)-3-methylphenoxy]-1*H*-pyrazolo[4,3-*c*]pyridine;

15

4,6-dimethyl-5-[4-(1*H*-pyrrolo[3,2-*c*]pyridin-4-yloxy)phenyl]pyridazin-3(2*H*)-one;

(-)-1,5-dimethyl-6-[2-methyl-4-(1*H*-pyrazolo[4,3-*c*]pyridin-4-yloxy)phenyl]pyrimidine-2,4(1*H*,3*H*)-dione;

4,6-dimethyl-5-[2-methyl-4-(1*H*-pyrrolo[3,2-*c*]pyridin-4-yloxy)phenyl]pyridazin-3(2*H*)-one, ENT-1;

20

4,6-dimethyl-5-[2-methyl-4-(1*H*-pyrrolo[3,2-*c*]pyridin-4-yloxy)phenyl]pyridazin-3(2*H*)-one, ENT-2

4-[4-(4,6-dimethyl-1-oxidopyrimidin-5-yl)-3-methylphenoxy]-1*H*-pyrazolo[4,3-*c*]pyridine;

6-methyl-5-[2-methyl-4-(1*H*-pyrrolo[3,2-*c*]pyridin-4-yloxy)phenyl]imidazo[1,2-*a*]pyrazine;

4-[4-(4,6-dimethylpyrimidin-5-yl)phenoxy]-1*H*-pyrrolo[3,2-*c*]pyridine;

25

2-(4,6-dimethylpyrimidin-5-yl)-5-(1*H*-pyrrolo[3,2-*c*]pyridin-4-yloxy)benzonitrile;

4-[3-chloro-4-(4,6-dimethylpyrimidin-5-yl)phenoxy]-1*H*-pyrrolo[3,2-*c*]pyridine;

(-)-1,5-dimethyl-6-[2-methyl-4-(1*H*-pyrrolo[3,2-*c*]pyridin-4-yloxy)phenyl]pyrazin-2(1*H*)-one;

4-[4-(4,6-dimethylpyrimidin-5-yl)-3-fluorophenoxy]-1*H*-pyrazolo[4,3-*c*]pyridine;

30

4-[4-(4,6-dimethylpyrimidin-5-yl)-3-methoxyphenoxy]-1*H*-pyrazolo[4,3-*c*]pyridine;

4-[3-chloro-4-(4,6-dimethylpyrimidin-5-yl)phenoxy]-1*H*-pyrazolo[4,3-*c*]pyridine;

(+)-1,5-dimethyl-6-[2-methyl-4-(1*H*-pyrazolo[4,3-*c*]pyridin-4-yloxy)phenyl]pyrazin-2(1*H*)-one;

4,6-dimethyl-5-[4-(1*H*-pyrazolo[4,3-*c*]pyridin-4-yloxy)phenyl]pyridazin-3(2*H*)-one; and

1,5-dimethyl-6-[4-(1*H*-pyrazolo[4,3-*c*]pyridin-4-yloxy)phenyl]pyrimidine-2,4(1*H*,3*H*)-dione,

5 or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 which is 4-[4-(4,6-dimethylpyrimidin-5-yl)-3-fluorophenoxy]-1*H*-pyrrolo[3,2-*c*]pyridine or a pharmaceutically acceptable salt thereof.

10 18. The compound of claim 1 which is 4-[4-(4,6-dimethylpyrimidin-5-yl)-3-methylphenoxy]-1*H*-pyrazolo[4,3-*c*]pyridine or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1 which is (-)-1,5-dimethyl-6-[2-methyl-4-(1*H*-pyrazolo[4,3-*c*]pyridin-4-yloxy)phenyl]pyrimidine-2,4(1*H*,3*H*)-dione or a pharmaceutically acceptable salt thereof.

15

20. The compound of claim 1 which is 4,6-dimethyl-5-[2-methyl-4-(1*H*-pyrrolo[3,2-*c*]pyridin-4-yloxy)phenyl]pyridazin-3(2*H*)-one, ENT-1 or a pharmaceutically acceptable salt thereof.

21. The compound of claim 1 which is 4,6-dimethyl-5-[2-methyl-4-(1*H*-pyrrolo[3,2-*c*]pyridin-4-yloxy)phenyl]pyridazin-3(2*H*)-one, ENT-2 or a pharmaceutically acceptable salt thereof.

20

22. The compound of claim 1 which is 2-(4,6-dimethylpyrimidin-5-yl)-5-(1*H*-pyrrolo[3,2-*c*]pyridine-4-yloxy)benzonitrile or a pharmaceutically acceptable salt thereof.

25 23. The compound of claim 1 which is (+)-1,5-dimethyl-6-[2-methyl-4-(1*H*-pyrazolo[4,3-*c*]pyridin-4-yloxy)phenyl]pyrazin-2(1*H*)-one or a pharmaceutically acceptable salt thereof.

24. A pharmaceutical composition comprising a compound according to any one of Claims 1-23 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

30

25. A compound according to any one of claims 1 to 23 or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder selected from schizophrenia, cognitive impairment, attention deficit hyperactivity disorder (ADHD), impulsivity, compulsive gambling, overeating, autism spectrum disorder, mild cognitive impairment (MCI), age-related cognitive decline, dementia, restless leg syndrome (RLS), Parkinson's disease, Huntington's chorea,

35 anxiety, depression, major depressive disorder (MDD), treatment resistant depression (TRD),

bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, systemic lupus erythematosus (SLE), hyperglycemia, atherosclerosis, 5 dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.